Moderna Surges 8% as Full Melanoma Readout Nears; BioNTech Ticks Up, Pfizer Slips

Shares of Moderna (NASDAQ:MRNA | MRNA Price Prediction) are trading as though the company’s messenger RNA (mRNA) cancer vaccine has already cleared its final test, even though the complete Phase 3 dataset has yet to be presented publicly. In afternoon trading, Moderna stock has risen 8%, reaching $204.60, extending a sharp rerating tied to the melanoma program. That gain stands far apart from a biotechnology group moving at a much slower pace.

At the same time, the iShares Biotechnology ETF (NASDAQ:IBB) is up 0.9%, a fraction of the gain in Moderna stock. For a broad-market gauge, the SPDR S&P 500 ETF Trust (NYSEARCA:SPY) is up 0.7%, which marks the rally in Moderna stock as a single-stock event driven by one pipeline story. Buyers are focused directly on the melanoma program, given the lead Moderna stock holds over both funds.

Checking in on the peers, BioNTech (NASDAQ:BNTX) stock is up 0.7% to $97.59, a modest move for another mRNA developer with cancer ambitions. Meanwhile, Pfizer (NYSE:PFE) shares are sliding 2% to $27.37, leaving the drugmaker on the weaker side of the vaccine trade. BioNTech and Pfizer once shared a vaccine franchise, and the split between them now tracks how close each company sits to a cancer catalyst.

What the Melanoma Program Means for Moderna

Merck (NYSE:MRK) is Moderna’s partner on intismeran, a personalized mRNA cancer vaccine coupled with Merck’s Keytruda. In August, Moderna and Merck announced that intismeran met the primary endpoint of a Phase 3 trial in melanoma patients whose tumors had already been surgically removed. Patients on the combination went longer without their cancer returning or spreading than patients on Keytruda alone, a meaningful reduction in recurrence.

Moderna has yet to present the complete dataset from that trial. Full validation depends on that complete dataset. Citigroup analyst Geoff Meacham has noted this, and the data is expected at the European Society for Medical Oncology (ESMO) congress in Madrid later this month. Bank of America analyst Alec Stranahan has described the result as a watershed moment that effectively allows Moderna to diversify away from infectious disease and potentially eases persistent capital pressures.

Moderna Moves Apart From Biotech Peers

BioNTech is running a comparable personalized mRNA cancer immunotherapy, autogene cevumeran, in partnership with Genentech. That program targets adjuvant colorectal and pancreatic settings and is at an earlier stage than Moderna’s melanoma effort, which fits with BioNTech stock posting a far smaller gain.

Moderna shares were up 594% year to date through the prior session’s close, a revaluation built against a result nobody outside the trial has seen in full. An approved oncology franchise would give Moderna a second revenue pillar beside the company’s established infectious-disease vaccine business, a prospect that explains the enthusiasm and raises the cost of any disappointment in Madrid.

What to Watch Next

The ESMO presentation in Madrid is the next dated moment where the gap between the price of Moderna stock and the trial evidence either closes or widens. The key question is whether the complete dataset confirms the recurrence benefit Moderna and Merck described in August. A strong presentation could support Stranahan’s view, while any soft spots in the data could give weight to Meacham’s call for full validation.

For BioNTech and Pfizer, the Madrid data may serve mainly as a read on how the market values personalized cancer vaccines, and traders may want to watch whether BioNTech stock tracks the reaction in Moderna stock to the full data.

Moderna stock has already priced in a great deal of success, so the downside from a mixed presentation could be steep. Investors should consider that Moderna shares may have run far ahead of a dataset that’s still awaiting full public review.

Contact [email protected] for any questions or corrections.